Table 1.

Proportion of patients with no radiographic progression at week 48

N/N-obs	Week 48 (LE)			Week 48 (observed/LOCF)
	Placebo* 228/192	Baricitinib 2 mg 229/218	Baricitinib 4 mg 227/204	Placebo* 228/204	Baricitinib 2 mg 229/219	Baricitinib 4 mg 227/206
ΔmTSS, n (%)
≤0	150/192 (78.1)	175/218 (80.3)	169/204 (82.8)	151/204 (74.0)	172/219 (78.5)	169/206 (82.0)
≤0.5	150/192 (78.1)	183/218 (83.9)	174/204 (85.3)	166/204 (81.4)	188/219 (85.8)	179/206 (86.9)
≤SDC (1.7)	158/192 (82.3)	190/218 (87.2)	183/204 (89.7)†	174/204 (85.3)	197/219 (90.0)	190/206 (92.2)†

The response status is dichotomised from the change in mTSS that is imputed using LE or LOCF. Comparisons analysed using logistic regression model.

*These patients were initially randomised to placebo, but switched to baricitinib 4 mg at rescue or at week 24 prior to entry to RA-BEYOND.

†P ≤ 0.05 vs placebo.

Δ, change from baseline; LE, linear extrapolation; LOCF, last observation carried forward; mITT, modified intent-to-treat; mTSS, modified Total Sharp Score; n, number of mITT patients; N-obs, number of patients with non-missing baseline and ≥1 non-missing postbaseline mTSS data included in analysis; SDC, smallest detectable change.